3,3,5,5-tetramethylpiperidin-4-ol | 240401-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3,3,5,5-tetramethylpiperidin-4-ol
• 英文别名: 3,3,5,5-tetramethyl-4-piperidanol；3,3,5,5-Tetramethyl-4-piperidinol
• CAS: 240401-34-7
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: HWORGAXUKTTWOD-UHFFFAOYSA-N

物化性质

• 沸点：
  214.1±15.0 °C(Predicted)
• 密度：
  0.891±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3,3,5,5-tetramethyl-piperidin-4-one 在 sodium tetrahydroborate 作用下， 以 氯仿 为溶剂， 反应 2.0h， 生成 3,3,5,5-tetramethylpiperidin-4-ol
  参考文献：
  名称：

  EP1710235

  摘要：

  公开号：

文献信息

• [EN] SUBSTITUTED BENZIMIDAZOLONES AS ANTI-CANCER AGENTS<br/>[FR] BENZIMIDAZOLONES SUBSTITUÉS EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2020104820A1

  公开（公告）日：2020-05-28

  The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula (I) wherein X, R1, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6activity is implicated.

  本发明涉及作为BCL6（B细胞淋巴瘤6）活性抑制剂的Formula I化合物：Formula (I)其中X、R1、R2和R3在此处各自定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及BCL6活性所涉及的其他疾病或情况中的用途。
• Phthalazine compounds and therapeutic agents for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US20030105074A1

  公开（公告）日：2003-06-05

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: 1 wherein R 1 and R 2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R 1 is a chlorine atom, R 2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种治疗勃起功能障碍的邻苯二氮杂环化合物，其化学式如下，其药理学上可接受的盐或水合物：1其中，R1和R2相同或不同，表示卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X表示氰基、硝基、卤素原子、可能被取代的羟肟基或可能被取代的杂环基；Y表示杂环基、可能被取代的芳基、可能被取代的炔基、烯基、烷基、可选取代的饱和或不饱和4-至8环胺环，所述的环胺化合物是单环化合物、双环化合物或螺环化合物；l是1到3的整数；但当l为1或2时，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基，Y为取代有羟基的5-或6环胺环时，不在此范围内。
• PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION
  申请人：Eisai Co., Ltd.

  公开号：EP1057819A1

  公开（公告）日：2000-12-06

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8- membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; 1 is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种作为勃起功能障碍治疗剂的酞嗪化合物，由下式、其药理学上可接受的盐或其水合物代表： 其中R1和R2彼此相同或不同，代表卤素原子、可被卤素原子取代的C1至C4烷基、可被卤素原子取代的C1至C4烷氧基或氰基；X代表氰基、硝基、卤素原子、可被取代的羟基亚氨基或可被取代的杂芳基；Y 代表杂芳基、可被取代的芳基、可被取代的炔基、烯基、烷基、任选取代的饱和或不饱和 4 至 8 位氨基环，环胺化合物是单环化合物、双环化合物或螺环化合物；1 是 1 至 3 的整数；但不包括以下情况：l 是 1 或 2，X 是氰基、硝基或氯原子，R1 是氯原子，R2 是甲氧基，Y 是被羟基取代的 5 或 6 位胺环。
• EXTRACTS OF MARASMINS ANDROSACEUS L.ES, PIPERDINONE DERIVATIVES AND THE USE AS ANTIHYPERTENSIVE AGENTS
  申请人：Beijing Tuolin Medicine Science and Technology Co., Ltd.

  公开号：EP1710235A1

  公开（公告）日：2006-10-11

  The present invention relates to Marasmius androsaceus L.es Fr extract, a compound of formula I, or pharmaceutically acceptable salts thereof, and to methods for their preparation, pharmaceutical composition comprising the same as well as use of the extract or the compound in the preparation of a medicament for the prevention and/or treatment of hypertension and its related diseases.

  本发明涉及 Marasmius androsaceus L.es Fr 提取物、式 I 的化合物或其药学上可接受的盐，以及它们的制备方法、包含它们的药物组合物以及提取物或化合物在制备预防和/或治疗高血压及其相关疾病的药物中的用途。
• Marasmius androsaceus l.es fr extract, piperidone derivative, and their use for the preparation of antihypertensives
  申请人：Yang Jichu

  公开号：US20070160625A1

  公开（公告）日：2007-07-12

  The present invention relates to Marasmius androsaceus L.es Fr extract, a compound of formula I, or pharmaceutically acceptable salts thereof, and to methods for their preparation, pharmaceutical composition comprising the same as well as use of the extract or the compound in the preparation of a medicament for the prevention and/or treatment of hypertension and its related diseases.